vancomycin has been researched along with gatifloxacin in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (58.06) | 29.6817 |
| 2010's | 12 (38.71) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Cohen, MA; Ellsworth, E; Gage, JW; Gibson, GW; Gracheck, SJ; Hanna, DL; Huband, MD; Skerlos, LA; Stier, MA; Sulavik, MC; Zurack, M | 1 |
| Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Béliveau, C; Labbé, AC; Laverdière, M; Louie, T; Maccannell, D; Pépin, J; Poirier, L; Savoie, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Aung, TT; Bai, Y; Beuerman, RW; Cao, D; Koh, JJ; Koh, WL; Lakshminarayanan, R; Li, J; Lim, F; Lin, H; Lin, S; Liu, S; Pang, LM; Pervushin, K; Qiu, S; Salleh, SM; Tan, DT; Verma, C; Zhou, L; Zou, H | 1 |
| Lynch, AS; Ma, Z | 1 |
| Brozovic, A; Dowson, CG; Gazvoda, M; Košmrlj, J; Lloyd, A; Osmak, M; Proud, C; Roper, DI; Vajs, J | 1 |
| Aung, TT; Beuerman, RW; Cao, D; Koh, JJ; Lakshminarayanan, R; Li, J; Lim, F; Lin, S; Liu, S; Ren, L; Tan, DT; Verma, C; Wang, L; Wang, Y; Zou, H | 1 |
| Aung, TT; Beuerman, RW; Cao, D; Koh, JJ; Lakshminarayanan, R; Lim, F; Lin, S; Liu, S; Ren, L; Sin, WLW; Tan, DTH; Wang, L; Zhou, L | 1 |
| McCracken, GH | 1 |
| Longworth, DL | 1 |
| Gottlieb, T; Leroi, MJ; Siarakas, S | 1 |
| Tipperman, R | 1 |
| Gordon, YJ; Kowalski, RP; Mah, FS; Romanowski, EG; Yates, KA | 1 |
| Flynn, HW; Harper, T; Miller, D | 1 |
| Callegan, MC; Farrand, AJ; Novosad, BD; Robinson, ML; Wiskur, BJ | 1 |
| Ermertcan, S; Gülden, E | 1 |
| Cohen, JA; Davis, MJ; Dennis, RF; Epstein, RJ | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
3 review(s) available for vancomycin and gatifloxacin
| Article | Year |
|---|---|
Pharmacodynamics of gatifloxacin in experimental models of pneumococcal meningitis.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Child; Disease Models, Animal; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Fluoroquinolones; Gatifloxacin; Humans; Meningitis, Pneumococcal; Naphthyridines; Rabbits; Streptococcus pneumoniae; Vancomycin | 2000 |
Microbial drug resistance and the roles of the new antibiotics.
Topics: Acetamides; Anti-Infective Agents; Atovaquone; Aza Compounds; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Moxifloxacin; Naphthoquinones; Oxazolidinones; Proguanil; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Vancomycin; Vancomycin Resistance; Virginiamycin | 2001 |
Pharmacologic considerations for cataract surgery.
Topics: Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Cataract Extraction; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ophthalmic Solutions; Quinolines; Triamcinolone Acetonide; Vancomycin | 2004 |
28 other study(ies) available for vancomycin and gatifloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Pyrrolidines; Quinazolinones; Topoisomerase II Inhibitors | 2007 |
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.
Topics: Adult; Aged; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Community-Acquired Infections; Cross Infection; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Female; Hospitalization; Humans; Incidence; Male; Middle Aged; Prognosis; Quebec; Ribotyping; Risk Factors | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
Topics: Amino Acids; Animals; Anti-Bacterial Agents; Cell Membrane; Drug Resistance, Multiple, Bacterial; Gram-Positive Bacterial Infections; Magnetic Resonance Spectroscopy; Mice; Microbial Sensitivity Tests; Rabbits; Structure-Activity Relationship; Unilamellar Liposomes; Xanthones | 2015 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Diaryltriazenes as antibacterial agents against methicillin resistant Staphylococcus aureus (MRSA) and Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Humans; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Mycobacterium smegmatis; Triazenes | 2017 |
Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.
Topics: Animals; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Methicillin-Resistant Staphylococcus aureus; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Staphylococcal Infections; Surface-Active Agents; Xanthones | 2017 |
Semisynthetic Flavone-Derived Antimicrobials with Therapeutic Potential against Methicillin-Resistant Staphylococcus aureus (MRSA).
Topics: Animals; Anti-Bacterial Agents; Arginine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Membrane; Cell Survival; Drug Resistance, Bacterial; Fibroblasts; Flavones; Hemolysis; Humans; Keratitis; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred C57BL; Microbial Sensitivity Tests; Molecular Mimicry; Rabbits; Staphylococcus aureus; Structure-Activity Relationship | 2017 |
E test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin, and linezolid.
Topics: Acetamides; Anti-Infective Agents; Aza Compounds; Clostridioides difficile; Clostridium Infections; Cross Infection; Diarrhea; Fluoroquinolones; Fusidic Acid; Gatifloxacin; Humans; Linezolid; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Oxazolidinones; Quinolines; Sensitivity and Specificity; Vancomycin | 2002 |
The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar (gatifloxacin 0.3%) in a NZW rabbit model.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents, Local; Cefazolin; Corneal Ulcer; Disease Models, Animal; Drug Resistance, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Ophthalmic Solutions; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.
Topics: Acetamides; Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Biological Availability; Coagulase; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Microbiological Techniques; Moxifloxacin; Oxazolidinones; Quinolines; Staphylococcal Infections; Staphylococcus; Vancomycin; Virginiamycin | 2007 |
Toward improving therapeutic regimens for Bacillus endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Bacillus cereus; Biological Availability; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Electroretinography; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Rabbits; Retina; Vancomycin; Vitreous Body | 2008 |
[In vitro activities of quinupristin/dalfopristin in combination with vancomycin and gatifloxacin against Staphylococcus aureus and Enterococcus faecium clinical isolates].
Topics: Anti-Bacterial Agents; Drug Combinations; Drug Synergism; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Humans; Staphylococcus aureus; Vancomycin; Virginiamycin | 2009 |
Culture-positive endophthalmitis after implantation of intraocular Collamer lens.
Topics: Adult; Anti-Bacterial Agents; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Humans; Lens Implantation, Intraocular; Lenses, Intraocular; Microsurgery; Postoperative Complications; Prednisolone; Staphylococcal Infections; Staphylococcus epidermidis; Vancomycin; Visual Acuity; Vitreous Body | 2009 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |